NASDAQ:GPCR Structure Therapeutics Q1 2026 Earnings Results & Report $22.04 -0.27 (-1.19%) As of 11:48 AM Eastern This is a fair market value price provided by Massive. Learn more. Structure Therapeutics beat analyst earnings expectations in its Q1 2026 results, released May 7, 2026. The company reported EPS of -$0.35 versus the -$0.39 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 7, 2026TimeAfter Market ClosesConference Call4:00 PM ET Structure Therapeutics EPS ResultsActual EPS-$0.35Consensus EPS -$0.39Beat/MissBeat by +$0.04One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersStructure Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$11.11 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsStructure Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Structure Therapeutics Q1 2026 Earnings FAQ Did Structure Therapeutics beat earnings estimates for Q1 2026? Structure Therapeutics (NASDAQ:GPCR) reported earnings of -$0.35 per share for Q1 2026, beating the consensus estimate of -$0.39. The report was announced on Thursday, May 7, 2026. When is Structure Therapeutics' next earnings date? Structure Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Structure Therapeutics on the company's earnings history page. Structure Therapeutics Earnings HeadlinesStructure Therapeutics (NASDAQ:GPCR) Stock Rating Cut to Strong Sell at Wall Street ZenOctober 3, 2026 | americanbankingnews.comGPCR Share News TodaySeptember 24, 2026 | uk.investing.comThe AI Infrastructure Play Kevin O'Leary Is BackingKevin O'Leary became a strategic investor in a NASDAQ-listed AI infrastructure company, calling it essentially a power company. The firm expects up to 190 MW of Nordic data center capacity approaching ready-for-service status by 2027-2028, as similar capacity has recently been valued at roughly $1.7 million to $2 million per MW annually. Google plans to invest $15 billion in Finland's AI infrastructure, with Cerebras also building a 165 MW facility nearby.October 14 at 1:00 AM | The Tomorrow Investor (Ad)Structure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In FocusSeptember 22, 2026 | finance.yahoo.comStructure Therapeutics Inc ADR (GPCR)September 19, 2026 | za.investing.comStructure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comSee More Structure Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Structure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Structure Therapeutics and other key companies, straight to your email. Email Address About Structure TherapeuticsStructure Therapeutics (NASDAQ:GPCR) Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic and cardiopulmonary diseases. The company uses structure-based drug discovery and related technologies to identify therapies intended to address conditions with significant unmet medical needs. Its lead product candidate is GSBR-1290, an investigational oral small-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor being developed for obesity and type 2 diabetes. Unlike injectable GLP-1 therapies, the candidate is designed as an oral treatment. Structure Therapeutics is also advancing additional discovery and development programs targeting metabolic, cardiovascular and pulmonary diseases. Structure Therapeutics operates internationally, with activities and personnel in the United States and China. The company was formerly known as Shouyao Holdings and became a publicly traded company on the Nasdaq under the symbol GPCR in 2023. Its scientific and executive leadership includes experienced drug-discovery and biotechnology professionals, supported by a team focused on translating structural biology into potential medicines.View Structure Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
